NCT00480467View on ClinicalTrials.gov

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2006

Study Completion Date

August 31, 2007

Conditions
Alzheimer Disease
Interventions
DRUG

SAM-315

Trial Locations (1)

305-0856

Ibaraki Pref

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00480467 - Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males | Biotech Hunter | Biotech Hunter